Welsh stem cell company Cell Therapy Ltd. has granted Japanese drugmaker Daiichi Sankyo a license for Heartcel™, its promising cardiac regeneration medicine. Under the conditions of the deal, Daiichi Sankyo
For our latest Data Visualisation project, the Evolution Global Team analysed historical new drug approval statistics and the current clinical trials pipeline to identify trends that highlight the rise and
The UK’s Human Fertilisation and Embryology Authority (HFEA) has given the go-ahead for a select group of Francis Crick Institute researchers to edit the genomes of human embryos. The group,
Advanced Cell Diagnostics and Leica Biosystems have announced a comprehensive partnership to develop and commercialise tissue-based diagnostic tests based on ACD’s RNAscope in situ hybridisation (ISH) assays and Leica’s clinical
Thermo Fisher Scientific (NYSE:TMO) have announced an agreement to acquire Affymetrix (NASDAQ:AFFX) for approximately $1.3 billion, or $14.00 per share, in cash. The acquisition was unanimously approved by the boards
On August 31, 2015 Google Life Sciences and French pharma giant Sanofi announced that the two companies will work together on new digital technology and tools for the treatment of
Evolution’s 2015 Biopharmaceutical IPO Analysis was featured in a recent article on Forbes. Science & Business correspondent Arlene Weintraub’s article, titled “Will Wall Street Volatility Dampen The Sizzling Biotech IPO
In the first half of 2015 fifty therapeutics companies finalised their IPOs, raising over $5.17 billion across multiple global exchanges. Evolution Global Talent Attraction analysed the therapeutic targets and IPO
Evolution Global Talent Attraction’s latest market research report looks at the capacity and content of biopharmaceutical production in Europe, the Middle East and Africa. Rather than publish a lengthy report,
NantKwest, Inc. (formerly known as Conkwest, Inc.), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer,
Preclinical CRO Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has entered into a definitive agreement to acquire Celsis International Ltd. for $212 million in cash, subject
Celgene and Juno Therapeutics have announced a decade long collaboration to advance potentially groundbreaking immunotherapies for patients with cancer and autoimmune diseases. The two companies will leverage T cell therapeutic
The Intellectual Property and Science business of Thomson Reuters recently honoured Genentech Partnering and Seragon, and Regeneron and Avalanche with the Allicense 2015 Breakthrough Award for Deals of the Year.
Merck Millipore and Singulex, the developer and leading provider of Single Molecule Counting (SMC™) technology for clinical diagnostics and scientific discovery, have announced that they have entered into a definitive
With the Cancer Immunotherapy market forecast to increase to $9 billion by 2022, it’s no surprise that the burgeoning sector has attracted the attention of biotech and pharma investors across
